WO2010071587A1 - Complexe et méthode d'amplification de la libération nucléaire - Google Patents

Complexe et méthode d'amplification de la libération nucléaire Download PDF

Info

Publication number
WO2010071587A1
WO2010071587A1 PCT/SE2009/051450 SE2009051450W WO2010071587A1 WO 2010071587 A1 WO2010071587 A1 WO 2010071587A1 SE 2009051450 W SE2009051450 W SE 2009051450W WO 2010071587 A1 WO2010071587 A1 WO 2010071587A1
Authority
WO
WIPO (PCT)
Prior art keywords
cap
cargo
nuclear
nucleus
complex
Prior art date
Application number
PCT/SE2009/051450
Other languages
English (en)
Inventor
Edvard Smith
Pedro Moreno
Roger STRÖMBERG
Malgorzata Wenska
Original Assignee
Avaris Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avaris Ab filed Critical Avaris Ab
Priority to US13/140,070 priority Critical patent/US9067964B2/en
Priority to EP09833750.4A priority patent/EP2376518A4/fr
Publication of WO2010071587A1 publication Critical patent/WO2010071587A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical

Definitions

  • the present invention relates to the field of molecular biochemistry and medicine, and in particular to a new non-viral vector for transmembrane delivery of therapeutic molecules.
  • Non-viral vector development for gene therapy is a field where mechanisms for improving nucleic acid delivery to the nucleus have been studied but only limited success has so far been achieved.
  • the use of peptide nuclear localization signals (NLS) together with nucleic acids has been one of the most explored formats in trying to achieve better nuclear transfer of genetic material.
  • Nucleocytoplasmic transport of endogenous molecules is a regulated process where small molecules are able to diffuse through the nuclear pore complex of the nuclear membrane while molecules >40 kDa require the use of a signal and energy-mediated processes.
  • Import of nuclear proteins requires nuclear localization signals (NLS) in the form of specific amino-acid sequences which mediate the interaction with carrier proteins [1].
  • NLS sequence is the SV40 large-T antigen. It mediates the interaction between the cargo protein, bearing the NLS signal, and an import receptor consisting of an adaptor protein, importin alpha, which directly binds the NLS signal, and importin beta which is the mediator of the actual import process through the nuclear pores [2].
  • RNAs in the form of small nuclear ribonuclear protein complexes (snRNP), use signals for nuclear import.
  • U snRNAs are comprised of the major spliceosomal U snRNAs, such as U1 , U2, U4 and U5 and are the major building units of the spliceosomal complex.
  • U snRNAs are transcribed in the nucleus by RNA polymerase Il after which they acquire a 7-methylguanosine (m 7 G) cap structure at their 5' end.
  • m 7 G 7-methylguanosine
  • This cap structure acts as a nuclear export signal that is recognized by the cap-binding complex (CBC).
  • CBC cap-binding complex
  • the CBC complex is in turn recognized by the export receptor CRM 1 with the help of PHAX adapter leading ultimately to the nuclear export of the U snRNA [6].
  • the U snRNA After release in the cytoplasm the U snRNA is recognized by the survival of motor neuron complex (SMN) that directs the proper assembly with a group of Sm proteins [7-10]. Subsequently the m 7 G cap is hypermethylated to a trimethylguanosine (1 ⁇ I3G) cap structure ( Figure 1) by the small-nuclear-RNA cap hypermethylase [11 , 12]. The matured snRNP is then imported back into the nucleus.
  • Sm 7 G cap is hypermethylated to a trimethylguanosine (1 ⁇ I3G) cap structure ( Figure 1) by the small-nuclear-RNA cap hypermethylase [11 , 12].
  • This nuclear transport involves two different pathways and two very distinct import signals, both of which, however, recruiting importin beta [13-16].
  • the first pathway uses a, still poorly defined, import signal present in the Sm core domain of the snRNP formed by the Sm proteins [17].
  • the second pathway involves the use of the 5' 2,2,7-trimethylated guanosine (nri3G) cap structure [18].
  • the m3G-CAP signal is recognized by the import adaptor protein snurportin (SPN 1) [14, 19, 20], which in turn is recognized by importin beta [14 - 16, 21].
  • Nuclear import of therapeutic molecules is of great importance for many applications.
  • specific targeting of exogenous proteins, such as antibodies, to the nucleus for the purpose of radioimmunotherapy is seen as a way to increase cytotoxicity effects in cancer cells [22].
  • one of the areas where nuclear targeting has been getting a lot of attention is the gene delivery/gene therapy field. This is especially true in non-viral or synthetic vector development, since these transport systems need to mimic most of the virus strategies used to overcome several cellular barriers of which the nuclear membrane is the ultimate one.
  • nucleic acid delivery has relied on the DNA sequence itself [23].
  • a plethora of other types of strategies for nucleic acid delivery has been based, however, on the direct or indirect attachment of NLS peptides to the nucleic acid molecules as a way to promote binding of the importin alpha/importin beta heterodimer to the nucleic acid construct and its subsequent nuclear translocation [24].
  • the SV40 large T antigene NLS (especially in its shortest form pkkkrkv) has been one of the most employed NLS peptide.
  • WO 00/04144 discloses the msG-CAP specific nucleus import receptor protein and the production and use thereof. The disclosure of WO 00/04144 focuses on the polypeptide, antibodies against it, and nucleic acids encoding the same. SUMMARY
  • the present inventors have explored the possibility to use m3G-CAP for the purpose of enhancing nuclear delivery of nucleic acids. It was surprisingly found that by coupling the nri3G pyrophosphate in its active form of imidazolide 5 to a 2'-O-methyl oligoribonucleotide possessing a 5' terminal end, resembling closely U snRNAs in vivo, the nuclear delivery of the oligonucleotide together with a large cargo protein was significantly increased. This nuclear transport was confirmed by microinjections into Xenopus oocytes and by a protein transfection method for cultured cells that delivers proteins to the cytosol.
  • the inventors make available a method and a complex for transmembrane transport of a molecular cargo into the nucleus using at least one non-peptide, nucleic acid based nuclear localization signal as defined in the claims, incorporated herein by reference.
  • One embodiment of the invention is a complex for facilitating transmembrane transport of a molecular cargo into the nucleus of a mammalian cell, wherein said complex comprises a molecular cargo coupled to at least one nucleic acid based nuclear localization signal, comprising 2,2,7-trimethylguanosine CAP (msG-CAP) or an analogue thereof.
  • msG-CAP 2,2,7-trimethylguanosine CAP
  • said nuclear localization signal is a synthetic m3G-CAP or an analogue thereof.
  • said molecular cargo is linked by covalent or non- covalent attachment to a modified 2,2,7-trimethyl-guanosineCAP (msG-CAP) structure as specified in Formula (I)
  • Ri is a cargo attached directly or a mono-, di or oligonucleotide (modified or unmodified) followed by a cargo unless the cargo is attached through R2 then Ri is a hydroxyl or a phosphate mono or diester;
  • R2 is methyl or H or any unsubstituted or substituted alkylgroup or is a cargo attached directly or a mono-, di or oligonucleotide (modified or unmodified) followed by a cargo;
  • R 4 is O or CH 2 ;
  • R5 is O or CH 2 ;
  • Re is O or CH 2 ;
  • X is OH or SH, or salts thereof
  • Y is OH or SH, or salts thereof
  • Z is OH or SH, or salts thereof
  • R7 is O, Or CH 2 ;
  • R 8 is NH 2 , H, or OH
  • R 9 is H, NH 2 Or OH
  • R11 is OH, or OCH 3 .
  • the ribose unit in brackets is chosen from a ribose, deoxyribose, a sugar residue or sugar replacement unit of a Locked Nucleic Acid (LNA), Peptide Nucleic Acid (PNA) or any other backbone modified nucleoside unit.
  • LNA Locked Nucleic Acid
  • PNA Peptide Nucleic Acid
  • both R 4 and Rs are CH2.
  • Rs is O when R 4 is Chb, or R 4 is O when Rs is Chb.
  • the complex further includes phosphorothioate modifications of the compound, as either isomer, at one or more of the positions X, Y and Z.
  • said molecular cargo comprises a therapeutic molecule chosen among natural and synthetic peptides, proteins, oligonucleotides, morpholino oligomers or nucleic acids linked to the above structure by a covalent linkage or by non-covalent interaction.
  • the inventors also make available a method for transmembrane transport of a molecular cargo into the nucleus of a mammalian cell, wherein said molecular cargo is coupled to at least one nucleic acid based nuclear localization signal comprising a 2,2,7-trimethylguanosine CAP (msG-CAP) structure or an analogue thereof.
  • msG-CAP 2,2,7-trimethylguanosine CAP
  • said nuclear localization signal is a synthetic m3G-CAP or an analogue thereof.
  • nuclear delivery of said molecular cargo is achieved by covalent or non-covalent attachment to at least one modified 2,2,7-trimethylguanosineCAP (msG-CAP) structure as specified in formula I.
  • msG-CAP modified 2,2,7-trimethylguanosineCAP
  • said molecular cargo comprises a therapeutic molecule chosen among natural and synthetic peptides, proteins, oligonucleotides, morpholino oligomers or nucleic acids linked to the above structure by a covalent linkage or by non-covalent interaction.
  • the inventors also make available the use of 2,2,7-trimethylguanosine CAP (nri3G- CAP) or an analogue thereof for the manufacture of a medicament.
  • the therapeutic utility of the complex and the method is substantiated in an example where the m3G-CAP was shown to be functionally relevant in achieving an increased splice correction when combining it with an antisense oligonucleotide.
  • Figure 1 illustrates the msG-CAP structure.
  • Figure 2 shows the synthesis of m3G-5'-pyrophosphorylimidazolide.
  • Figure 3 shows the reaction scheme for attachment of the m3G-CAP to oligonucleotides, also called the capping reaction.
  • Figure 4 shows the structure of the nri3G-CAP-PMO2 oligonucleotide.
  • FIG. 5 is a schematic representation of Streptavidin-Alexa488 (STV)+, i.e. the nri3G- cap oligonucleotide construct used in the nuclear transport assays. Image proportions are exaggerated for a better understanding.
  • Figure 6a is a western blot showing the accumulation of Streptavidin complexes in Xenopus oocyte nuclei after cytoplasmic injections.
  • Figure 6b is a graph showing the quantification of the western blot results by densitometry.
  • Figure 7a consists of four phase contrast microscopy pictures, showing the localization of fluorescent Streptavidin when bound to an average of 3 - 4 biotinylated 2'-O-methyl RNA oligonucleotides with (pictures A, B) or without (pictures C, D) addition of m3G-CAP respectively.
  • Figure 7b consist of two fluorescent microscopy pictures; showing lack of nuclear accumulation when LNA oligonucleotides were hybridized to non-capped oligos (picture A), and strong nuclear accumulation when LNA oligonucleotides were hybridized to m 3 G-capped oligonucleotides (picture B).
  • Figure 8a is a graph showing fold-induction of splice-correction after transfection of HeLa Luc705mut with 2'-O-methyl antisense oligonucleotides at 0.2 ⁇ M for 24h.
  • Fig. 8b is a blot showing the result of RT-PCR of the total cellular RNA.
  • Figure 9 shows the synthesis scheme for compounds 16 and 17.
  • Figure 10 highlights the difference between compounds 16 and 17.
  • Figure 11 shows the time dependence of the disappearance of the native m3G-cap (compound 16) in cell medium with 10 % serum.
  • Figure 12 shows the time dependence of the disappearance of the methylenephosphonate modified m3G-cap (compound 17) in cell medium with 10 % serum.
  • Figure 13 shows the time dependence of the disappearance of compound 16 (squares) and 17 (circles) in cytosolic extract.
  • analogue is intended to encompass chemical modifications of the compounds presented, these modifications being such that can be performed by a skilled person after having obtained the information given in the present description and examples.
  • An analogue is further defined as a compound having retained the function of the starting compound, but where the modifications convey improved properties such as increased stability, reduced immunogenicity etc.
  • nucleic acids here encompasses both synthetic and natural oligonucleotides and analogues, such as PNA, LNA etc, including constructs built on these components, such as siRNA and Zorro molecules, e.g. Zorro-LNA [44].
  • the term "about” is used to indicate a deviation of +/- 2 % of the given value, preferably +/- 5 % and most preferably +/- 10 % of the numeric values, when applicable.
  • One embodiment of the invention concerns a complex for facilitating transmembrane transport of a molecular cargo into the nucleus of a mammalian cell, wherein said molecular cargo is coupled to at least one nucleic acid based nuclear localization signal.
  • said nuclear localization signal is a non-peptide, non-viral nucleic acid based nuclear localization signal.
  • said nuclear localization signal comprises 2,2,7-trimethylguanosine CAP (nri3G-CAP).
  • Said nuclear localization signal is either a natural or a synthetic nri3G- CAP.
  • An example of a modified 2,2,7-trimethyl-guanosineCAP structure is specified in Formula (I) which is designed to give retained transport signal function while enhancing resistance towards degradation:
  • Ri is a cargo attached directly or a mono-, di or oligonucleotide (modified or unmodified) followed by a cargo unless the cargo is attached through R2 then Ri is a hydroxyl or a phosphate mono or diester;
  • R2 is methyl or H or any unsubstituted or substituted alkyl group or is a cargo attached directly or a mono-, di or oligonucleotide (modified or unmodified) followed by a cargo;
  • R 4 is O or CH 2 ;
  • R 5 is O or CH 2 ;
  • R 6 is O or CH 2 ;
  • X is OH or SH, or salts thereof
  • Y is OH or SH, or salts thereof
  • Z is OH or SH, or salts thereof
  • R 7 is O, Or CH 2 ;
  • R 8 is NH 2 , H, or OH
  • R 9 is H, NH 2 Or OH
  • R11 is OH, Or OCH 3 .
  • the ribose unit in brackets is chosen from a ribose, deoxyribose, the sugar residue or sugar replacement unit of a Locked Nucleic Acid (LNA), Peptide Nucleic Acid (PNA) or any other backbone modified nucleoside unit.
  • LNA Locked Nucleic Acid
  • PNA Peptide Nucleic Acid
  • both R 4 and Rs are CH2.
  • R5 is O when R 4 is CH2, or R 4 is O when R5 is CH2.
  • one embodiment involves phosphorothioate modifications of the compound according to Formula I, as either isomer, i.e., with one or more of the positions X, Y and Z being SH or a salt thereof. Such modifications are performed in order to make the compound more resistant towards degradation in vivo while still recognizable by the nuclear transport system.
  • the complex can be used for transmembrane transport of any molecular cargo, such as molecules not naturally taken up by the nucleus, or only insufficiently capable of being taken up by the nucleus.
  • said molecular cargo comprises a therapeutic molecule chosen among natural and synthetic peptides, proteins, oligonucleotides, morpholino oligomers or nucleic acids linked to the above structure by a covalent linkage or by non-covalent interaction.
  • Another embodiment of the invention is an improved method for transmembrane transport of a molecular cargo into the nucleus of a mammalian cell, wherein said molecular cargo is coupled to at least one nucleic acid based nuclear localization signal.
  • said nuclear localization signal is a non-peptide, non-viral nucleic acid based nuclear localization signal.
  • said nuclear localization signal comprises a 2,2,7- trimethylguanosine CAP (m3G-CAP) structure.
  • said nuclear localization signal is either a naturally occurring or synthetic m3G-CAP.
  • a preferred embodiment of the invention is a method for transmembrane transport of a molecular cargo into the nucleus of a mammalian cell, wherein nuclear delivery of said molecular cargo is achieved by covalent or non-covalent attachment to a modified 2,2,7-trimethylguanosine CAP structure as defined by Formula (I).
  • said molecular cargo comprises any molecular cargo, such as molecules not naturally taken up by the nucleus, or only insufficiently capable of being taken up by the nucleus.
  • the cargo is a therapeutic molecule chosen among natural and synthetic peptides, proteins, oligonucleotides, or nucleic acids linked to the above structure by a covalent linkage or by non-covalent interaction.
  • the inventors believe that suitable modifications to the triphosphate function can render the m3G-cap structure more resistant towards enzymatic degradation.
  • the inventors have performed experiments in 10 % serum (fetal calf serum) and cytosolic extract (HeLa cells), indicating that the tested modifications have a stabilizing effect in vivo.
  • R7 modifications to R7 (and some of the R10, Rn modifications) can render the nri3G-cap structure more resistant towards decomposition and hence enhance shelf- life, an important property of a drug delivery complex.
  • R10 and Rn are also possible sites for modifications.
  • the substituents Rs and R9 are intended to cover the most common purine bases, since the main interaction is stacking between the nri3G and this base, and both A and G can be accepted in this position.
  • Non-limiting examples of modified msG-caps with cargo where the cargo is merely schematically indicated, are given below:
  • the embodiments of the invention constitute a first approach to use the U snRNA nri3G-CAP as an adaptor signal for the increase of nuclear transport of external cargoes such as natural and synthetic peptides, proteins, oligonucleotides, or nucleic acids.
  • the inventors first designed a construct composed of a fluorescent Streptavidin (STV-Alexa 488) and a defined number of RNA oligonucleotides with or without the nri3G-CAP at their 5' ends.
  • the inventors initially chose the Xenopus oocyte to test their system, since the study of U snRNAs/snRNP particles has been well documented in these cells in previous experiments by others.
  • the Xenopus oocyte it was found that nuclear transport of the U1 snRNA species was very much dependent on the presence of the m3G-cap in the RNA [18, 42].
  • the experiments showed that the m3G-CAP was sufficient for enhancing the nuclear import of a cargo protein. More specifically, by using a defined construct with two to three msG-capped RNA oligos, which were spaced away from the cargo STV, the inventors achieved an at least 6-fold enhancement in nuclear import as compared to the uncapped counterpart.
  • the particles are also different in the way that the m3G-CAP is sitting on a short oligonucleotide that is bound to a STV through the use of a relatively long spacer (here 34 atoms long) with biotin at its end (see Figure 5) which shows that the cargo can be spaced away from the import complex formed by the nri3G and the import receptors.
  • a relatively long spacer here 34 atoms long
  • biotin at its end
  • the inventors used a novel system where they performed a nuclear import assay in live mammalian cells by using a protein delivery reagent that is able to release the cargo into the cytosol of cells.
  • This system resembles the pathways taken by molecules in gene delivery protocols, so it is believed to be relevant in assessing the properties of the m3G-CAP for future uses in the gene delivery field.
  • the nri3G signal was able to direct nuclear translocation of the cargo quite efficiently.
  • the inventors used a splice correction assay where antisense oligonucleotides are employed to correct a malfunctioning splice occurring due to a mutation in the beta-globin intron.
  • antisense oligonucleotides with an incorporated m3G-CAP structure an increased splice correction was achieved, measured by increase of activity of a Luciferase reporter construct.
  • the delivery of simple single-stranded oligonucleotides to nucleus of cells and especially dividing cells should be a very useful embodiment of the invention.
  • oligonucleotide in this case having a nuclear targeting moiety in the oligonucleotide can help to increase local nuclear concentrations by redirecting oligonucleotides diffusing out of the nucleus.
  • an additional factor that could be influencing the activity of the msG-capped oligonucleotides cannot be excluded, which is a possible localization of these oligonucleotides into specific splice regions, since the m3G-CAP is naturally present in U snRNPs that are targeted to splice compartments of the nucleus. Therefore, the complex and method of the invention are believed to be particularly advantageous.
  • a possible area of use is gene silencing using bifunctional oligonucleotides, so called U1 adaptors, binding to the U1 small nuclear RNA component of the U1 snRNP splicing factor.
  • Splice correction is a promising treatment strategy, currently used e.g. in experimental treatments for Duchenne Muscular Dystrophy with the aim of converting this severe form of muscle disease into the more mild form called Becker disease (these patients lack the inclusion of certain exons, while they maintain the reading- frame).
  • Altering splicing could also result in many other effects such as inducing forms of proteins causing apoptosis in e.g. tumour cells, by converting one splice- form into another, or removing un-natural exons formed by mutations.
  • siRNA short interfering RNA
  • Zorro molecules such as Zorro-LNA.
  • the invention is also applicable to other methods and therapies involving RNA interference, where the complex and method can be used to introduce RNAi or siRNA molecules to the desired location in the cell.
  • splice corruption is an approach where a transcript necessary for survival of the cells is disturbed or destroyed. This could be a promising approach against tumour cells.
  • the complex and method according to the invention offers an advantage in that effective and targeted transmembrane delivery makes it possible to reduce the amount of therapeutic substance administered to the patient. This is favourable as it reduces the cost for synthesizing the therapeutic substance, e.g. an oligonucleotide or the like. Another advantage is the reduction of the risk for side-effects, a particular consideration when life-long treatments of chronic diseases is contemplated, e.g. Duchenne Muscular Dystrophy.
  • the initial experiments performed by the inventors clearly show the capabilities of an m3G-capped oligonucleotide in directing nuclear translocation of a cargo molecule in different assay systems. Consequently this is believed to be the preponderant mechanism for the increased activity, in the conditions of the tested system, of the nri3G-capped antisense oligonucleotides.
  • RNA molecules that are naturally present in endogenous RNA molecules can have potential advantages over some methods based on association of very positively charged NLS peptides with nucleic acids. These peptides can interact unspecifically by electrostatic interactions with the nucleic acids with possible implications in the recognition of the NLS by the import receptors (hampered recognition of the NLS signal by the import receptors) making it difficult to control the properties of the nucleic acid-NLS complex and to assess what is their actual mechanism in transfection protocols.
  • the modified m3G-Cap has shown to be easier to synthesize that the natural form. Further, the modified m3G-Cap is 5' selective, which is an advantage when coupling it to a molecular cargo, or linker.
  • linkers can be used, including nucleic acid based linkers, where "nucleic acids” include both natural and synthetic oligonucleotides and their analogues such as PNA, LNA etc.
  • the invention as defined in the claims includes the use of at least one m3G-Cap, but it is contemplated, depending on the size and properties of the cargo, that more than one localization signal or m3G-Cap is attached to the cargo.
  • a lager cargo can be covalently or non-covalently linked to 1 , 2, 3, 4 or more localization signals. It is envisioned that a combination of localization signals, including but not limited to nri3G- Cap like structures, can be used.
  • the complex has the potential of handling molecules of highly varying sizes.
  • the inventors synthesized a compound according to the invention, and showed that nri3G-capped RNA oligonucleotides are able to direct nuclear accumulation of a cargo protein (fluorescent Streptavidin) in Xenopus oocytes, and in a mammalian cell line.
  • a cargo protein fluorescent Streptavidin
  • the inventors also showed that msG-capped 2'-O-Methyl RNA antisense oligonucleotides have increased efficiency in a splice correction assay using Hel_a/l_uc705 cells.
  • Reverse phase and ion exchange HPLC was carried out on a Jasco HPLC system using the following columns: analytical Reprosil-Pur C18-AQ (250x3 mm) at 1 mL/min flow rate, preparative Reprosil-Pur C18-AQ (250x20 mm) at 10 mL/min flow rate, or Dionex Nucleo-Pac PA-100 (4x250 mm) at 1 mL/min flow rate.
  • Buffers for reverse phase chromatography (Reprosil columns) were: A, 50 mM TEAA pH 6.5, B, 50 mM TEAA pH 6.5 in 50% CH3CN.
  • Buffers for ion exchange chromatography were: A, 20 mM NaOAc in 30% CH 3 CN, B, 0.3 M LiOCIO 4 , 20 mM NaOAc in 30% CH3CN.
  • Mass spectra were obtained by using a Micromass LCT electrospray time-of-flight (ES-TOF) instrument and the MAXENT program for calculation of masses from multiply charged ions.
  • the non-capped oligonucleotides were purchased from Fidelity Systems Inc. of Gaithersburg, MD, USA (PM02-p) and Eurogentech of Seraing, Belgium (AS705-p) and reconstituted in nuclease free water (Qiagen).
  • AS705-p and PMO2-p were converted to the msG-capped derivatives nri3G- CAP-AS705 and m 3 G-CAP-PMO2 by reaction with the m 3 G-5'- pyrophosphorylimidazolide 5 in a Mn(II) catalysed capping reaction [32].
  • Synthesis of the nri3G 5'-pyrophosphateimidazolide 5, was modified compared to previously published procedures [32, 33] in order to simplify larger scale synthesis.
  • the 5'- Pyrophosphate 3 was synthesised in a new one-pot, five-step synthesis, based on reported reactions [34-37]. See Figure 2.
  • Pyrophosphorylimidazolide 5 (680 nmol, 0.51 mg, 10 eq) was dissolved in 0.1 mL of 0.2 M N-methylmorpholine » HCI buffer pH 7.0, containing MnCb (10 eq in 0.1 mL) and added to lyophilized oligonucleotide PMO2-p (7OD at 260 nm, 68 nmol).
  • the reaction mixture was kept at 3O 0 C for 7 days after which it was treated with EDTA solution (0.1 M, 0.005 mL) and analyzed by ion-exchange HPLC.
  • EDTA solution 0.1 M, 0.005 mL
  • U2OS cell line was obtained from American Type Culture Collection (ATCC; HTB-96, Rockville, MD, USA) and the HeLa/Luc705 [38] comes originally from Dr. R KoIIe (University of North Carolina at Chapel Hill). Cells were cultured in Dulbecco's modified eagle medium (DMEM) supplemented with 10% (v/v) heat inactivated fetal calf serum (Invitrogen) in a 37°C humidified 5% CO2 incubator.
  • DMEM Dulbecco's modified eagle medium
  • Invitrogen 10% (v/v) heat inactivated fetal calf serum
  • Streptavidin-Alexa488 (Molecular Probes) + oligonucleotide constructs were formed by incubating 3 ⁇ g STV (Streptavidin) reconstituted in 1x phosphate buffered saline (PBS, pH 7.4) with 2 - 4 times molar amount of biotinylated oligonucleotide constructs. The volume was adjusted with nuclease free water (Qiagen) to have a final concentration of 329 ng STV/ ⁇ l and the incubation proceeded for 2 h at room temperature and if not used the same day the constructs were stored at 4°C.
  • Xenopus laevis oocytes stage IV-V were prepared and collagenised as follows: a lobe of the frog ovary, about 2-3 ml volume, was minced with a pair of scissors in ORs buffer and then digested with 7U of a preparation of purified collagenase (Liberase Blendzyme 3, Roche) for 2-2.5 Hrs at 19°C during gentle agitation. The collagenase treatment is discontinued when the lobes of connected oocytes have been dispersed into individual oocytes.
  • the oocytes are then rinsed in OR2 (82 mM NaCI; 2.5 mM KCI; 1 mM Na2HPO4; 5 mM HEPES pH 7.8; 1 mM MgCI; 1 mM CaCI) and stored at 19°C in OR2 buffer with 10 ⁇ g Gentamicin / ml (SIGMA).
  • the prepared STV-oligo constructs Prior to microinjections the prepared STV-oligo constructs were spun down at 16,000 x g for 5 minutes. A volume of 41.4 nl of STV-oligo constructs was injected in the cytoplasm of the oocyte using the Nanoinjector 2000 TM pump (World Precision Instruments, Inc) followed by incubation at 19°C in OR2 buffer for 4h.
  • oocyte nuclei were manually dissected in nuclear dissection buffer (140 mM KCI; 0.5 mM MgSO 4 ; 20 mM Tris-HCI pH 7.2) and collected directly in 2x Laemelli sample buffer.
  • U2OS cells were seeded on top of coverslips in a 24-well plate with DMEM+10% FCS the day before transfection so that they were confluent or close to confluency the next day.
  • Streptavidin-Alexa488 (Molecular Probes) + oligonucleotide constructs ( Figure 5) were formed by incubating 2 ⁇ g STV (Streptavidin) reconstituted in IxPBS buffer (pH 7.4) with 2 - 4 times molar amount of biotinylated oligonucleotide constructs for 2 h at room temperature 20 mM Hepes buffer (pH 7.4) was then used to bring the total volume up to 100 ⁇ l and then 3.5 ⁇ l of PULSin transfection reagent (PolyPlus- Transfection, New York, USA) was added. The mixture was vortexed and left to incubate for 15 min at room temperature.
  • the cells were washed twice with PBS and 900 ⁇ l of pre-warmed OPTImem (Invitrogen) was added to the wells.
  • the PULSin complexes were then added to the cells and left to incubate for 4 h. Subsequently, the medium was discarded and the cells washed twice with pre-warmed OPTImem. Finally, 500 ⁇ l of OPTImem was added to the wells after which the cells were further incubated for 2 - 3 h. The cells were then analysed by fluorescence microscopy and confocal microscopy.
  • HeLa/Luc705 cells were pre-seeded at a density of 35,000 cells per well in a 24-well plate the day before transfection in order to have between 40% and 50% confluency the next day.
  • Antisense oligonucleotide constructs were transfected by using Oligofectamine reagent (Invitrogen) and following the manufacturer's protocol.
  • Cells were harvested in Luciferase lysis buffer (25 mM TAE, 10 % glycerol, 1 mM EDTA, 1 % Triton-X100) after 24h and the level of luciferase expression was analysed based on a luciferase activity assay (Luciferase assay Kit, Biothema AB, Handen, Sweden). Total protein was measured using a BCA protein assay (Micro BCATM protein assay kit, Thermo Scientific-Pierce Protein Research Products, Rockford, USA)
  • RT-PCR was done by isolating total RNA from cells with RNeasy plus kit (QIAGEN) from which a total of 3 ng of RNA was then used in each reaction (total volume per reaction was 20 ⁇ l) with the ONE STEP RT-PCR kit (QIAGEN) and following the manufacturers protocol.
  • the primers used were:
  • the program for the RT-PCR was as follows: (55°C, 35 min + 95°C, 15 min) x1 cycle + (94°C, 30 s + 55°C, 30 s + 72°C, 30 s) x 29-30 cycles + 72°C, 10 min final extension.
  • the PCR products were analysed in a 2% agarose gel in 1x TBE buffer and visualized by SYBR-GoId (Invitrogen, Molecular Probes) staining. Gel images were captured by a Fluor-S gel documentation system (BioRad) with the Quantity One software (BioRad). RESULTS
  • nroG-capped RNA oligonucleotides are able to direct nuclear accumulation of a cargo protein in Xenopus oocytes
  • oocytes are very big cells with a large nucleus and easy to inject, secondly it is quite straightforward to study the isolated compartments (cytoplasm and nuclei) since the nuclei are relatively easy to isolate by manual dissection.
  • a further very important feature is that the oocyte is a non-dividing cell which thereby maintains the integrity of its nuclear membrane throughout the experiments.
  • the inventors then decided to study the nuclear accumulation of a construct constituted of a fluorescent Streptavidin (STV) bound to 2-3 biotinylated 2'-O-methyl RNA oligonucleotides with (CAP-PM02) or without (p-PM02) m 3 G-CAP modification (Figure 5).
  • STV protein itself has a molecular weight of around 53 kDa and the addition of 2-4 biotinylated oligonucleotides equals a total MW for the construct of between 60-70 kDa. This should make it difficult for the STV-oligonucleotide construct to enter the nucleus by passive diffusion alone, since 45-50 kDa is the known cut-off of the nuclear pore.
  • the inventors were already gaining insight into the possible properties of the msG-CAP-oligo as a defined adaptor for enhancing nuclear transport a cargo when the NLS signal is not in its close proximity.
  • Fig. 6A shows western blot using anti-Streptavidin probing. Each lane corresponds to one group of 4 nuclei pooled together. Lanes 1-2-7-8: nuclei dissected from oocytes injected with STV-CAP-RNA; lanes 3-4-5-6: nuclei dissected from oocytes injected with STV-RNA. Lower panel shows a protein loading control by staining the gel with coomassie blue after transfer.
  • the inventors performed fluorescent microscopy of isolated nuclei after cytoplasmic injections of the STV complexes.
  • the nuclei were isolated in pairs each representing a cytoplasmic injection of STV with (nucleus 1) or without (nucleus 2) capped oligonucleotide.
  • By putting the nuclei side by side it was easily seen that only the oocyte injected with STV-CAP oligonucleotide showed a green fluorescent nucleus while the nucleus from the other oocyte did not show any detectable fluorescence confirming the previous results of the western blot where the capped oligonucleotide conferred enhanced nuclear transport capacity to the STV- oligo complex.
  • nroG-capped RNA oligonucleotides are able to direct nuclear accumulation of a cargo protein in mammalian cells after cytosolic delivery by a transfection reagent
  • the inventors also tested if the previous constructs would behave similarly when delivered to a mammalian cell line and, importantly, by a transfection method that resembles the delivery routes of many gene delivery protocols. For this, the inventors employed a method of protein and peptide delivery through the use of a reagent that promotes uptake of proteins into the cytosol of cells (PULSin) after endocytosis of protein-reagent complexes.
  • PULSin a reagent that promotes uptake of proteins into the cytosol of cells
  • nuclei and cytoplasm of cells are marked by N and C, respectively, in the phase contrast pictures.
  • Solid white arrows indicate examples of cells counted as positive for nuclear enrichment; Solid white arrowheads point to cells counted as negative for nuclear enrichment; open white arrowheads point to aggregates of fluorescent STV complexes that can occur during the transfection procedure; open rectangular boxes were drawn around the "STV-CAP nuclear bodies" formed by increased accumulation of STV complexes in the nucleus.
  • LNA biotinylated locked nucleic acid
  • RNA antisense oligonucleotides have increased efficiency in a splice correction assay lntron splicing is a mechanism occurring only in the nuclei of cells and for this reason the inventors used a splice correction assay to check for any increased activity of splice antisense oligos that could arise from their possible nuclear enrichment by the use of the m3G-CAP signal.
  • the inventors used HeLa/Luc705 cells stably expressing a luciferase gene, where the coding region was interrupted by a mutated beta-globin intron at position 705. By targeting the region containing the mutation with antisense oligos one can redirect the splicing so that the luciferase mRNA is successfully translated into protein [43].
  • the oligonucleotide used for this study was a 2'-O-methyl oligoribonucleotide based on the same sequence as reported by Kang et al [43] but with a 3nt addition (AUA) to its 5' end.
  • the oligonucleotide included an overhanging phosphate group at this same 5' end that was used later for the addition of the m3G-CAP (msGpppAUA-).
  • a control oligonucleotide with a scrambled sequence was also tested at the highest concentration with or without msG-CAP. Both versions had no effect in correcting aberrant luciferase splicing attesting to that the m3G-CAP addition had no effect itself in restoring luciferase activity.
  • the inventors confirmed the luciferase activity results with RT-PCR to directly show that the increase in luciferase activity was due to a correction of the aberrantly spliced luciferase by the antisense oligonucleotides.
  • RT-PCR total RNA from the treated cells to RT-PCR.
  • restoration of luciferase activity is correlated with an increase in the correctly spliced pre-mRNA and this was always more efficient when having capped-oligonucleotides compared to non-capped (See Fig. 8b, where the upper ban (268 bp) and lower band (142 bp) correspond to the aberrant and correct luciferase mRNA, respectively.
  • Cp1 and p1 correspond to the antisense oligonucleotide (AS705) with (oligo Cp1) or without (oligo p1) m3G-CAP added.
  • Cp2 and p2 correspond to the scrambled (control) antisense oligonucleotide with (oligo Cp2) or without (oligo p2) m3G-CAP).
  • N-Butyryl-5'-O- monomethoxytrityl-2'-O-methyladenosine 7 (100 mg, 0.16 mmol) was dried by evaporation of added dry pyridine (5 ml_) under reduced pressure and finally by keeping on a vacuum pump for 30 min. Dry pyridine was added (2 ml_) and the solution was put into ice-bath whereupon benzoyl chloride was added (1.2eq, 0.19 mmol, 22.2 ⁇ l_) and after 10 min the ice-bath was removed and the reaction was allowed to warm up and was then left stirring overnight at room temperature.
  • 3'-O-Benzoyl-N 6 -butyryl-2'-O-methyl adenosine 5'-H-phosphonate 10 was dried by evaporation of added dry pyridine (5 ml_) and 30 min drying on a vacuum pump. To the compound was added pyridine (0.8 ml_), triethylamine (5eq, 0.44 mmol, 61 ⁇ l_) and trimethyl silyl chloride (5eq, 0.44 mmol, 55.7 ⁇ l_).
  • Example 4 Stability studies of models of the native cap (16) and a methylenephosphonate cap (17) in cell medium containing 10% serum and cvtosolic extract (1-3 mg/mL total protein)
  • Figures 11 and 12 show the time dependence of the disappearance of the native m3G-cap (16) and the methylenephosphonate modified m3G-cap (17) in cell medium with 10% human serum (duplicate runs), which displays increased stability towards degradation in biological liquids, for the compound with the modified triphosphate function.
  • Figure 13 shows a comparison of the time dependence of the disappearance of compounds 16 (squares) and 17 (circles) in cytosolic extract (1.3 mg/mL of total protein) which shows increased stability towards degradation in a cytoplasmic environment, for the compound with the modified triphosphate function.
  • snRNAs contain specific SMN-binding domains that are essential for snRNP assembly. MoI Cell Biol, 24, 2747-2756.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Il est démontré que l'emploi d'au moins un signal de localisation nucléaire basé sur un acide nucléique comportant une coiffe m3G-CAP naturelle ou synthétique augmente le transport transmembranaire d'une cargaison moléculaire, en particulier de grandes molécules, jusqu'au noyau. La présente invention concerne l'emploi d'une coiffe m3G-CAP naturelle et synthétique et son effet sur un signal de localisation nucléaire d'extrémité 5' d'ARN naturel, composé d'une coiffe de type 2,2,7-triméthylguanosine (m3G-CAP) couplée à une Streptavidine fluorescente dans l'un des exemples, et à un oligonucléotide antisens dans un autre. Il est démontré qu'une coiffe m3G-CAP modifiée par méthylènephosphonate présente une stabilité améliorée dans le sérum humain et dans un extrait cytosolique.
PCT/SE2009/051450 2008-12-18 2009-12-17 Complexe et méthode d'amplification de la libération nucléaire WO2010071587A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US13/140,070 US9067964B2 (en) 2008-12-18 2009-12-17 Complex and method for enhancing nuclear delivery
EP09833750.4A EP2376518A4 (fr) 2008-12-18 2009-12-17 Complexe et méthode d'amplification de la libération nucléaire

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13892508P 2008-12-18 2008-12-18
US61/138,925 2008-12-18

Publications (1)

Publication Number Publication Date
WO2010071587A1 true WO2010071587A1 (fr) 2010-06-24

Family

ID=42269040

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2009/051450 WO2010071587A1 (fr) 2008-12-18 2009-12-17 Complexe et méthode d'amplification de la libération nucléaire

Country Status (3)

Country Link
US (1) US9067964B2 (fr)
EP (1) EP2376518A4 (fr)
WO (1) WO2010071587A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014153258A3 (fr) * 2013-03-14 2015-01-08 Epeius Biotechnologies Corporation Gène codant pour des thymidine kinases améliorées

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023183825A2 (fr) * 2022-03-21 2023-09-28 Ptc Therapeutics Gt, Inc. Thérapie génique de maladies associées à ush2a

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998034942A2 (fr) * 1997-02-06 1998-08-13 Inspire Pharmaceuticals, Inc. Dinucleotides et leur utilisation en tant que modulateurs d'epuration mucociliaire et de frequence des battements ciliaires
WO2008016473A2 (fr) * 2006-07-28 2008-02-07 Applera Corporation ANALOGUES DE COIFFES DE NUCLÉOTIDE D'ARNm

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998034942A2 (fr) * 1997-02-06 1998-08-13 Inspire Pharmaceuticals, Inc. Dinucleotides et leur utilisation en tant que modulateurs d'epuration mucociliaire et de frequence des battements ciliaires
WO2008016473A2 (fr) * 2006-07-28 2008-02-07 Applera Corporation ANALOGUES DE COIFFES DE NUCLÉOTIDE D'ARNm

Non-Patent Citations (16)

* Cited by examiner, † Cited by third party
Title
BHINDI ET AL., AM J PATHOL, vol. 171, 2007, pages 1079 - 88
BHINDI R. ET AL: "Brothers in arms: DNA enzymes, short interfering RNA, and the emerging wave of small-molecule nucleic acid-based gene-silencing strategies", AMERICAN JOURNAL OF PATHOLOGY, vol. 171, no. 4, October 2007 (2007-10-01), pages 1079 - 1088, XP003026452 *
FISCHER U. ET AL: "Diversity in the signals required for nuclear accumulation of U snRNPs and variety in the pathways of nuclear transport", JOURNAL OF CELL BIOLOGY, vol. 113, no. 4, 1991, pages 705 - 714, XP003026455 *
FREEMAN S. ET AL: "Acyclic Nucleosides as Antiviral Compounds", APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY - PART B MOLECULAR BIOTECHNOLOGY, vol. 5, no. 2, 1996, pages 125 - 137, XP008089303 *
KADOKURA ET AL., J ORGANIC CHEMISTRY, vol. 65, no. 17, 2000, pages 5104 - 5113
KADOKURA ET AL., TETRAHEDRON LETTERS, vol. 42, 2001, pages 8853 - 6
KADOKURA M. ET AL: "Solid-phase synthesis of a 5'-terminal TMG-capped trinucleotide block of U1 snRNA", TETRAHEDRON LETTERS, vol. 42, no. 50, 2001, pages 8853 - 8856, XP004322559 *
KADOKURA M. ET AL: "Synthesis of 4-thiouridine, 6-thioinosine, and 6-thioguanosine 3',5'-O-bisphosphates as donor molecules for RNA ligation and their application to the synthesis of photoactivatable TMG-capped U1 snRNA fragments", JOURNAL OF ORGANIC CHEMISTRY, vol. 65, no. 17, 2000, pages 5104 - 5113, XP003026454 *
MORENO P.M.D. ET AL: "A synthetic snRNA m3G-CAP enhances nuclear delivery of exogenous proteins and nucleic acids", NUCLEIC ACIDS RESEARCH, vol. 37, no. 6, 2009, pages 1925 - 1935, XP003026456 *
PATANI G.A. ET AL: "Bioisosterism: A rational approach in drug design", CHEMICAL REVIEWS, vol. 96, no. 8, 1996, pages 3147 - 3176, XP000652176 *
See also references of EP2376518A4 *
SEKINE M. ET AL: "Chemical synthesis of a 5'-terminal TMG-capped triribonucleotide m32,2,7G5'pppAmpUmpA of U1 RNA", JOURNAL OF ORGANIC CHEMISTRY, vol. 61, no. 13, 1996, pages 4412 - 4422, XP000608149 *
SEKINE M. ET AL: "Synthesis of TMG-capped RNA-DNA chimeric oligonucleotides", TETRAHEDRON LETTERS, vol. 44, no. 8, 2003, pages 1703 - 1707, XP004405305 *
SEKINE, TETRAHEDRON LETTERS, vol. 44, 2003, pages 1703 - 7
STRASSER A. ET AL: "Structural basis for m3G-cap-mediated nuclear import of spliceosomal UsnRNPs by snurportin1", EMBO JOURNAL, vol. 24, no. 13, 2005, pages 2235 - 2243, XP003026453 *
WORCH R. ET AL: "Specificity of recognition of mRNA 5' cap by human nuclear cap-binding complex", RNA, vol. 11, no. 9, 2005, pages 1355 - 1363, XP002523957 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014153258A3 (fr) * 2013-03-14 2015-01-08 Epeius Biotechnologies Corporation Gène codant pour des thymidine kinases améliorées
US9925276B2 (en) 2013-03-14 2018-03-27 Epeius Biotechnologies Corporation Thymidine kinase gene
US9999683B2 (en) 2013-03-14 2018-06-19 Epeius Biotechnologies Corporation Method for identifying and treating a patient having tumor lesions comprising administering a gene therapy retroviral vector particle comprising a mutated HSV-thymidine kinase (HSV-TK) polynucleotide
US10350302B2 (en) 2013-03-14 2019-07-16 Genvivo, Inc. Thymidine kinase diagnostic assay for gene therapy applications
US10610603B2 (en) 2013-03-14 2020-04-07 Genvivo, Inc. Thymidine kinase gene
US11253611B2 (en) 2013-03-14 2022-02-22 Genvivo, Inc. Thymidine kinase diagnostic assay for gene therapy applications
US11364307B2 (en) 2013-03-14 2022-06-21 Genvivo, Inc. Thymidine kinase gene

Also Published As

Publication number Publication date
US9067964B2 (en) 2015-06-30
US20110306138A1 (en) 2011-12-15
EP2376518A4 (fr) 2013-12-04
EP2376518A1 (fr) 2011-10-19

Similar Documents

Publication Publication Date Title
JP7353301B2 (ja) 肝臓外送達
AU2022206704A1 (en) Nanoparticle formulations for delivery of nucleic acid complexes
CN108135924B (zh) 用于跨膜递送分子的化合物和方法
JP2021073183A (ja) 修飾二本鎖ｒｎａ剤
DK2999785T3 (en) SERPINA1-IRNA COMPOSITIONS AND PROCEDURES FOR USE THEREOF
JP2021046396A (ja) ホスホルアミダイト化学を使用する骨格修飾モルホリノオリゴヌクレオチド及びキメラの合成
JP2000501414A (ja) 生体分子の細胞取り込みを高めるリガンド
US11918600B2 (en) Nucleic acid, pharmaceutical composition and conjugate containing nucleic acid, and use thereof
US10945955B2 (en) Artificial exosome composition and related methods
JP2022501057A (ja) トランスサイレチン（ＴＴＲ）ｉＲＮＡ組成物及びＴＴＲ関連眼疾患を治療又は予防するためのその使用方法
JP2022060357A (ja) ＡＳＧＲ１発現を阻害するためのＲＮＡｉコンストラクトおよびその使用方法
KR20230026992A (ko) Trem 조성물 및 그의 용도
JP2021520207A (ja) アンチセンス鎖の５’末端でビニルホスホネートを有するｓｉＲＮＡ
KR20190104392A (ko) 분자의 막투과 전달을 위한 화합물 및 방법
JP2021502411A (ja) 標的遺伝子の発現を抑制するためのジチオリン酸結合を含む核酸
JP2023527413A (ja) Ｔｒｅｍ組成物及びそれに関連する方法
WO2019063843A1 (fr) Compositions et procédés pour la libération d'arnm dans des cellules hépatiques
TW202242108A (zh) 經修飾trem之組合物及其用途
US20230104113A1 (en) Delivery of compositions comprising circular polyribonucleotides
US9067964B2 (en) Complex and method for enhancing nuclear delivery
JP2022532652A (ja) オリゴヌクレオチドの経口送達
JP2023504186A (ja) 標的化された核酸送達のためのペプチドドッキング賦形剤
JPH0799976A (ja) 修飾オリゴヌクレオチド
JP2021509406A (ja) 分子の膜貫通送達のための化合物および方法
CN116940324A (zh) 脂质纳米颗粒球形核酸

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09833750

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009833750

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13140070

Country of ref document: US